Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)

Lung Cancer

Volumn 70, Issue 3, 2010, Pages 301-307

  Morère, Jean François ^a   Bréchot, Jeanne Marie ^a   Westeel, Virginie ^b   Gounant, Valerie ^c   Lebeau, Bernard ^d   Vaylet, Fabien ^e   Barlési, Fabrice ^f   Urban, Thierry ^g   Souquet, Pierre Jean ^h   Debieuvre, Didier ⁱ   Baudrin, Laurence ^j   Zalcman, Gérard ^k   Morin, Franck ^j   Milleron, Bernard ^c   Moro Sibilot, Denis ^l  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c HÔPITAL TENON   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e PERCY MILITARY HOSPITAL   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ Centre Hospitalier Intercommunal   (France)

^j IFCT   (France)

^k CAEN UNIVERSITY HOSPITAL   (France)

^l HÔPITAL MICHALLON   (France)

more..

Author keywords

Chemotherapy; Gefitinib; Lung cancer; Performance status 3

Indexed keywords

DOCETAXEL; GEFITINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG ERUPTION; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77956805350     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.03.003     Document Type: Article

References (34)

1. Group NM-AC Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
2. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 9:1618-1626.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
4. Paesmans M., Sculier J.P., Libert P., Bureau G., Dabouis G., ThiriauxF J., et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995, 13:1221-1230.
5. Soria J.C., Brisgand D., Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?. Ann Oncol 2001, 12:1667-1670.
6. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
7. Sweeney C.J., Zhu J., Sandler A.B., Joan S., Chandra P.B., Corey L., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594. Cancer 2001, 92:2639-2647.
8. Lilenbaum R.C., Herndon J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005, 23:190-196.
9. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994, 12:1821-1826.
10. Anderson H., Hopwood P., Stephens R.J., Thatcher N., Cottier B., Nicholson M., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. Br J Cancer 2000, 83:447-453.
11. Kosmidis P.A., Dimopoulos M.-A., Syrigos K., Nicolaides C., Aravantinos G., Boukovinas I., et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase ii study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007, 2:135-140.
12. Roszkowski K., Pluzanska A., Krzakowski M., Smith A.P., Saigi E., Aasebo U., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000, 27:145-157.
13. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.-Y., et al. Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
14. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
15. Charlson M., Pompei P., Ales K., MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
17. Ando M., Ando Y., Hasegawa Y., Shimokata K., Minami H., Wakai K., et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001, 85:1634-1639.
18. Blagden S.P., Charman S.C., Sharples L.D., Magee L.R.A., Gilligan D. Performance status score: do patients and their oncologists agree?. Br J Cancer 2003, 89:1022-1027.
19. Lilenbaum R., Cashy J., Hensing T., Young S., Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008, 3:125-129.
20. Ranson M., Davidson N., Nicolson M., Falk S., Carmichael J., Lopez P., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000, 92:1074-1080.
21. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91:66-72. Elderly Lung Cancer Vinorelbine Italian Study Group T.
22. O'Brien M.E.R., Socinski M.A., Popovich A.Y., Bondarenko I.N., Tomova A., Bilynskyi B.T., et al. Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:728-734.
23. Perrone F., Di Maio M., Gallo C., Gridelli C. Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 2004, 22:5018-5020. For the Multicenter Italian Lung Cancer in the Elderly Study I.
24. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
25. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.-L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
26. Hesketh P.J., Wozniak A.J., Hirsch F.R., Spreafico A., Moon J., Mack P.C., et al. Southwest oncology group phase ii trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 2008, 3:1026-1031.
27. Lilenbaum R., Axelrod R., Thomas S., Dowlati A., Seigel L., Albert D., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008, 26:863-869.
28. Goss G., Ferry D., Wierzbicki R., Laurie S.A., Thompson J., Biesma B., et al. Randomized phase ii study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009, [JCO.2008.2018.4408].
29. Bridges B.B., Thomas L., Hausner P.F., Doyle L.A., Bedor M., Smith R., et al. Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2, 3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. Lung Cancer 2008, 61:61-66.
30. Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., Mikami I., et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27:1394-1400.
31. Cullen M., Steven N., Billingham L., Gaunt C., Hastings M., Simmonds P., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988-998. the Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours Trial G.
32. Lilenbaum R., Rubin M., Samuel J., Boros L., Chidiac T., Seigel L., et al. A randomized phase ii trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:306-311.
33. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
34. Mok T.S., Wu Y.-L., Thongprasert S., Yang C.-H., Chu D.-T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.